21.08.2023 • News

Ecovyst Appoints Colleen Grace Donofrio as Vice President – Environment and Sustainability

Ecovyst, a specialty catalyst and sulfuric acid recycling provider, announced today that Colleen Grace Donofrio has been appointed as its Vice President – Environment and Sustainability.

“I am excited to have Colleen join the team to lead our environmental and sustainability programs,” said Kurt Bitting, CEO of Ecovyst. “Colleen’s experience and enthusiasm will help further enhance Ecovyst’s award winning sustainability programs and bolster our efforts to develop service offerings that enable our customers to meet their sustainability goals."

Previously, Donofrio was a shareholder in Babst, Calland, Clements and Zomnir, an environmental law practice based in Pittsburgh, PA. There, she served as outside counsel to Ecovyst and its predecessors since 2005. She replaces Elaine T. Simpson, who has retired from Ecovyst after a two-decade-long career with Ecovyst and its predecessors. 

Ecovyst contains two business units, Ecoservices which focus on sulfuric acid production and recycling in North America for the refining industry, water treatment, mining and other industries; and Catalyst Technologies, which supplies silica catalysts, catalyst supports, and zeolites for various catalytic applications.

Ecovyst names Colleen Grace Donofrio as Vice President – Environment and...
Ecovyst names Colleen Grace Donofrio as Vice President – Environment and Sustainability. © Ecovyst

Company

Ecovyst Inc.



US

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read